35,000 Shares in Disc Medicine, Inc. $IRON Bought by Seven Grand Managers LLC

Seven Grand Managers LLC acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 35,000 shares of the company’s stock, valued at approximately $2,779,000.

Other institutional investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd bought a new position in Disc Medicine during the 4th quarter worth $33,000. Aster Capital Management DIFC Ltd bought a new position in Disc Medicine during the 3rd quarter worth $38,000. KBC Group NV bought a new position in Disc Medicine during the 4th quarter worth $80,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after buying an additional 490 shares during the last quarter. Finally, Avanza Fonder AB grew its stake in Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after buying an additional 235 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Trading Up 2.4%

Shares of Disc Medicine stock opened at $69.76 on Thursday. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of -10.54 and a beta of 0.93. The business has a fifty day simple moving average of $66.22 and a 200-day simple moving average of $74.09. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, equities analysts forecast that Disc Medicine, Inc. will post -6.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. BMO Capital Markets lowered their price objective on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Stifel Nicolaus decreased their price target on Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Truist Financial decreased their price target on Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Finally, Wedbush decreased their price target on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.30.

Insider Buying and Selling at Disc Medicine

In other news, CFO Jean M. Franchi sold 6,257 shares of the company’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total value of $433,234.68. Following the completion of the sale, the chief financial officer owned 64,333 shares in the company, valued at $4,454,416.92. This represents a 8.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider William Jacob Savage sold 5,731 shares of the company’s stock in a transaction on Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the completion of the sale, the insider owned 79,480 shares of the company’s stock, valued at approximately $5,275,882.40. This trade represents a 6.73% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 19,766 shares of company stock valued at $1,327,321. Insiders own 3.76% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.